Fig. 2From: First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETsEx-vivo biodistribution of A [225Ac]Ac-DOTA-JR11 and B [177Lu]Lu-DOTA-JR11 at 4, 24, 48 and 72 h post-injection (n = 3 mice/group). Data are presented as the percentage of injected activity per gram of tissue (% IA/g)Back to article page